- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Artivion Inc (AORT)
Artivion Inc stock price live, this page displays NYSE AORT stock exchange data. View the AORT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Artivion Inc real time stock price chart below.
What Is the Artivion Inc Stock Price Today?
The Artivion Inc stock price today is 29.14.
What Is the Stock Symbol for Artivion Inc?
The stock symbol for Artivion Inc is "AORT."
What Stock Exchange Does Artivion Inc Trade On?
Artivion Inc is listed and trades on the NYSE stock exchange.
Is Artivion Inc a Good Stock to Buy?
Determining whether Artivion Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AORT quote. (ISIN: US2289031005)
What Is the Artivion Inc Stock Price Today?
The Artivion Inc stock price today is 29.14.
What Is the Stock Symbol for Artivion Inc?
The stock symbol for Artivion Inc is "AORT."
What Stock Exchange Does Artivion Inc Trade On?
Artivion Inc is listed and trades on the NYSE stock exchange.
Is Artivion Inc a Good Stock to Buy?
Determining whether Artivion Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AORT quote. (ISIN: US2289031005)
NYSE
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.27
29.24
52 wk Range
19.16
48.25
AORT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
28.2729.24
52 wk Range
19.1648.25
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
AORT Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
42.03
Upside
+44.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Not profitable over the last twelve months
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 42.03
(+44.22% Upside)
Artivion Inc Earnings Call Summary for Q2/2026
- Q2 revenue rose 9% constant-currency to $125.8M, beating $120.06M forecast; stent grafts up 12%, On-X valves up 18% year-over-year.
- Artivion received FDA PMA approval for AMDS in late June; completed Endospan acquisition with NEXUS U.S. launch planned for January 2027.
- Adjusted EBITDA margin compressed 90bps to 21% on higher R&D spending and acquisition costs; free cash flow negative $12M versus positive $11.7M prior year.
- Full-year 2026 guidance unchanged at 7-11% revenue growth ($480-496M) and $92-99M adjusted EBITDA despite Q2 beat due to timing factors.
- Management expects 2027 to be 'meaningfully free cash flow positive' with NEXUS revenue beginning January; net leverage stands at 3.1x at quarter-end.
Last Updated: 2026-08-06, 05:38 p/m
Read Full TranscriptEarnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.28 / 0.01
Revenue / Forecast
125.76M / 120.06M
Compare AORT to Peers and Sector
Metrics to compare | AORT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAORTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −445.2x | −1.6x | −0.4x | |
PEG Ratio | −5.29 | 0.00 | 0.00 | |
Price/Book | 3.2x | 2.1x | 2.6x | |
Price / LTM Sales | 3.0x | 1.9x | 3.1x | |
Upside (Analyst Target) | 42.8% | 11.7% | 47.9% | |
Fair Value Upside | Unlock | 7.3% | 6.3% | Unlock |
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Artivion (AORT) Stock Price Today?
The Artivion stock price today is 29.14 USD.
What Stock Exchange Does Artivion Trade On?
Artivion is listed and trades on the New York Stock Exchange.
What Is the Stock Symbol for Artivion?
The stock symbol for Artivion is "AORT."
What Is the Artivion Market Cap?
As of today, Artivion market cap is 1.42B USD.
What Is Artivion's Earnings Per Share (TTM)?
The Artivion EPS (TTM) is -0.07.
When Is the Next Artivion Earnings Date?
Artivion will release its next earnings report on Oct 29, 2026.
From a Technical Analysis Perspective, Is AORT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Artivion Stock Split?
Artivion has split 2 times.
How Many Employees Does Artivion Have?
Artivion has 1800 employees.
What is the current trading status of Artivion (AORT)?
As of Aug 17, 2026, Artivion (AORT) is trading at a price of 29.14 USD, with a previous close of 28.41 USD. The stock has fluctuated within a day range of 28.27 USD to 29.24 USD, while its 52-week range spans from 19.16 USD to 48.25 USD.
What Is Artivion (AORT) Price Target According to Analysts?
The average 12-month price target for Artivion is 42.03 USD, with a high estimate of 48 USD and a low estimate of 38 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +44.22% Upside potential.
What Is the AORT Premarket Price?
AORT's last pre-market stock price is 29.47 USD. The pre-market share volume is 415.00, and the stock has decreased by 1.06, or 3.75%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.